Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vesleteplirsen - Sarepta Therapeutics

Next Previous
Drug Profile

Vesleteplirsen - Sarepta Therapeutics

Alternative Names: SRP 5051

Latest Information Update: 17 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines; Peptide drug conjugates; Peptides
  • Mechanism of Action Dystrophin expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 07 Feb 2025 Sarepta Therapeutics terminates the phase II MOMENTUM trial in Duchenne muscular dystrophy in USA, Canada, Belgium, Spain, Germany, Italy, Netherlands, Ireland and UK (IV) (NCT04004065) (EudraCT2019-000601-77)
  • 11 Mar 2024 Serepta Therapeutics plans to meet FDA to discuss next steps related to 5051-201 trial in second half of 2024.
  • 29 Jan 2024 Safety and efficacy data from part B of phase II MOMENTUM trial in Duchenne muscular dystrophy released by Sarepta Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top